rAAV-Based and Intraprostatically Delivered miR-34a Therapeutics for Efficient Inhibition of Prostate Cancer Progression

The authors found that miR-34a overexpression significantly inhibited the cell cycle, viability, and migration of prostate cancer cells by targeting its downstream genes.